Highlights Hemostemix Inc.

Equities

HEM

CA4236943060

Market Closed - Toronto S.E. Other stock markets 20:47:51 25/06/2024 BST			5-day change	1st Jan Change
0.04 ^CAD	-11.11%		-27.27%	-42.86%

06-11	Hemostemix Announces Strategic Manufacturing Partnership with Cytoimmune Therapuetics	CI
06-03	Hemostemix Inc. announced that it expects to receive CAD 2 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hemostemix Announces Strategic Manufacturing Partnership with Cytoimmune Therapuetics	06-10	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	02-06	CI
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	31/10/23	CI
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	15/09/23	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	10/08/23	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/05/23	CI
Hemostemix Hiring Four Biotechnologists in Montreal, Says Applying for Grants to Fund up to 75% of 5-Year Costs	23/01/23	MT
Hemostemix Announces Letter of Commitment For $250,000 of Funding by McGill University Health Centre Foundation	19/01/23	MT
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/11/22	CI
Hemostemix Inc. Announces Evolution of Patented Automated Cell Therapy System	15/11/22	CI
Hemostemix Announces NCP-01 Study to Address Pain	19/10/22	MT
Hemostemix Inc. Announces Exploring Clinical Trial Financing Alternatives	05/10/22	CI
Hemostemix Inc. agreed to Spin-Off PreCerv Inc.	30/08/22	CI
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections	30/08/22	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hemostemix Inc.

Equities

HEM

CA4236943060

Highlights

Filters